Cancer prevention by vaccination against induced antigens
Ended Awarded Last action
- Contract number
- 75N91019F00132
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,219,900
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Contract value 100% obligated
- $1,219,899.79 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$7,267 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,227,167 |
About this award
This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer Center is a comprehensive cancer center that regularly participates in federal research initiatives through prime and subcontract awards, including studies on tumor biology, experimental therapeutics, and cancer disparities. The University of Texas System also frequently supports federal grant-funded research projects across diverse scientific domains.
Quick answers
Who was awarded contract 75N91019F00132?
75N91019F00132 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 15, 2019.
How much is contract 75N91019F00132 worth?
The government has obligated $1,219,900 on 75N91019F00132.
Is contract 75N91019F00132 an order under another contract?
Yes. 75N91019F00132 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00132 competed?
The extent of competition for 75N91019F00132 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award